Viewing Study NCT05918640



Ignite Creation Date: 2024-05-06 @ 7:10 PM
Last Modification Date: 2024-10-26 @ 3:01 PM
Study NCT ID: NCT05918640
Status: RECRUITING
Last Update Posted: 2024-06-12
First Post: 2023-06-06

Brief Title: Lurbinectedin in FET-Fused Tumors
Sponsor: Childrens Hospital of Philadelphia
Organization: Childrens Hospital of Philadelphia

Study Overview

Official Title: Lurbinectedin in FET-Fusion Tumors LIFFT
Status: RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: LiFFT
Brief Summary: The purpose of this study is to find out if a drug called lurbinectedin the study drug is safe and effective at treating people with recurrent or relapsed solid tumors including Ewing sarcoma
Detailed Description: In this study the investigators will test the activity of lurbinectedin as a targeted therapy for FET FUS Ewing Sarcoma Breakpoint Region 1 EWRS1 TATA-Box-Binding Protein Associated Factor 15 TAF15 Ewing sarcoma is driven by the Ewing Sarcoma-Friend Leukemia Integration 1 Transcription Factor EWS-FLI1 Lurbinectedin has been shown to inhibit EWS-FLI1 and Ewing Sarcoma-Wilms Tumor Gene 1 EWS-WT1 in preclinical models Therefore the goal of this study is to see if Lurbinectedin can be used to inhibit EWS-FLI1 EWS-WT1 or other FET fusion proteins to drive tumor responses in patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None